X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

ChemAxon Software is Integrated into ChemPass’s Novel Drug Design Platform

Yuvraj_pawp by Yuvraj_pawp
5th December 2017
in Americas, News
ChemAxon Software is Integrated into ChemPass’s Novel Drug Design Platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

ChemAxon and ChemPass, jointly announce that several ChemAxon software components and toolkits are incorporated into ChemPass’ artificial intelligence design technology platform; and also, into the SynSpace software that has specifically been designed for medicinal chemists.

ChemPass built its new design software applying ChemAxon components that handle fundamental cheminformatics tasks and enable users to work with industry leading standard capabilities within SynSpace. Features such as; chemical drawing, structure checking and standardization, searching and enumeration – are all powered by the ChemAxon functionality as part of a long-term collaboration. As a result of the partnership, medicinal chemists and users alike will now have a platform that can expand the synthesizable chemical space for their projects while utilizing familiar industry standard methods.

Dr. Gergely Makara, CEO of ChemPass says; “We are very pleased with the scientific support ChemAxon provided and the flexibility of their cheminformatics components we have built into our technology. It enabled us to focus on the development of our core technologies, the synthetic artificial intelligence, synthesis know-how and design technology. The partnership with ChemAxon significantly accelerated the development progress, therefore SynSpace is now becoming available for all in the Cloud – bringing synthetic chemists closer to chemoinformatic solutions.”

ChemAxon’s CEO, Dr. Ferenc Csizmadia adds, “We believe that both our customers benefit from the collaboration and software integration. The ChemPass software has great potential in the medicinal chemistry design field and their unique scientific approach can help all users generate new ideas and develop novel leads and clinical candidates – And, ChemAxon will be able to assist drug discovery practitioners via a new avenue.”

About ChemAxon
ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the chemistry, biotechnology, pharmaceutical and agrochemical industries. We focus on active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA and sales and support offices in Europe, Japan and across North America.

About ChemPass
ChemPass is an artificial intelligence design technology company focusing on the development of software solutions that help chemists and medicinal chemists generate ideas, design novel scaffolds or lead analogs, and reach a significantly expanded synthesizable chemical space.
For further information please visit www.chempassltd.com

Contact:
Gergely Makara
gergely.makara@chempassltd.com

For further information about ChemAxon please visit:
www.chemaxon.com
contact sales@chemaxon.com

For media inquiries, please contact:
marketing@chemaxon.com

Previous Post

Scientists Create Successful Mass Production System for Bioengineered Livers

Next Post

Canon BioMedical products now available in Austria, Germany, and Switzerland

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Canon BioMedical products now available in Austria, Germany, and Switzerland

Canon BioMedical products now available in Austria, Germany, and Switzerland

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In